

blocked by hIgG
blocked by 5C4
MFI
500
400
300
200
100
0
Control
5C4
2D3
7D3
HuMab anti-PD-1 mAbs

FIG. 1A



blocked by hIgG
blocked by 5C4
MFI
1000
800
600
400
200
0
Control
4H1
HuMab anti-PD-1 mAbs

FIG. 1B



blocked by hIgG
blocked by 5C4
MFI
150
100
50
0
Control
17D8
HuMab anti-PD-1 mAbs

FIG. 1C



FITC-10H10 binding to
anti-hPD-L1 HuMab Ab-blocked CHO/PD-L1 cells
MFI (FITC)
0
10
20
30
40
50
60
70
80
90
100
hIgG1
5F8
7H1
10H10
1B12
3G10
10A5
11E6
12A4
12B7
13G4
Blocking Antibodies

FIG. 2A



FITC-3G10 binding to
anti-hPD-L1 HuMab Ab-blocked CHO/PD-L1 cells
MFI (FITC)
0
20
40
60
80
100
120
140
160
hIgG1
5F8
7H1
10H10
1B12
3G10
10A5
11E6
12A4
12B7
13G4
Blocking Antibodies

FIG. 2B



FITC-10A5 binding to
anti-hPD-L1 HuMab Ab-blocked CHO/PD-L1 cells
MFI (FITC)
0
20
40
60
80
100
120
140
hIgG1
5F8
7H1
10H10
1B12
3G10
10A5
1E6
12A4
12B7
13G4
Blocking Antibodies

FIG. 2C



FITC-11E6 binding to
anti-hPD-L1 HuMab Ab-blocked CHO/PD-L1 cells
MFI (FITC)
0
20
40
60
80
100
120
140
160
180
hIgG1
5F8
7H1
10H10
1B12
3G10
10A5
11E6
12A4
12B7
13G4
Blocking Antibodies

FIG. 2D



FITC-12A4 binding to
anti-hPD-L1 HuMab Ab-blocked CHO/PD-L1 cells
MFI (FITC)
0
10
20
30
40
50
60
70
80
hIgG1
5F8
7H1
10H10
1B12
3G10
10A5
11E6
12A4
12B7
13G4
Blocking Antibodies

FIG. 2E



FITC-13G4 binding to
anti-hPD-L1 HuMab Ab-blocked CHO/PD-L1 cells
MFI (FITC)
0
20
40
60
80
100
120
140
160
180
hIgG1
5F8
7H1
10H10
1B12
3G10
10A5
11E6
12A4
12B7
13G4
Blocking Antibodies

FIG. 2F



Blockade by hPD-L1 HuMabs of
biotin-12A4 binding to ES-2 cells
5F8
3G10
12B7
1B12
13G4
10H10
10A5
12A4
huIgG4
Biotin-MDX-1105 Binding (MFI)
3000
2000
1000
0
0.0001
0.01
1
100
Unconjugated Ab (nM)

FIG. 3



Melanoma 1 mg/kg
First occurrence of new lesion
Patient off study
Change in Target Lesions from Baseline (%)
Weeks since Treatment Initiation
100
90
80
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140

FIG. 4




FIG. 5




FIG. 6





FIG. 7



Association Between Pretreatment Tumor PD-L1 Expression and Clinical Response			
Response Status	PD-L1-Positive no. (%)	PD-L1-Negative no. (%)	Total no. (%)
CR/PR	9(36)	0	9(21)
Nonresponder	16*(64)	17(100)	33(79)
All Patients	25	17	42

Fisher's exact test for association P=0.006.

*Two patients categorized as nonresponders at the time of data analysis are still under evaluation.

FIG. 8A




FIG. 8B



Histoscore Average 5H1
Histoscore Average 28-8
300
250
200
150
100
50
0
1080754B NSCLC
1080766B NSCLC
1080790B NSCLC
1080993B NSCLC
T030668 Mel
T030744 Mel
1168657B Mel
T980747 Mel
1164619B Mel
1167809B Mel

FIG. 9



Melanoma 1 mg/kg
First occurrence of new lesion
Patient off study
Change in Target Lesions from Baseline (%)
220
200
180
160
140
120
100
80
60
40
20
0
-20
-40
-60
-80
-100
0
10
20
30
40
50
60
70
80
90
100
Weeks since Treatment Initiation

FIG. 10A



Melanoma 3 mg/kg
First occurrence of new lesion
Patient off study
Change in Target Lesions from Baseline (%)
Weeks since Treatment Initiation
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
0
10
20
30
40
50
60
70
80
90
100
110

FIG. 10B



Melanoma 10 mg/kg
First occurrence of new lesion
Patient off study
Change in Target Lesions from Baseline (%)
Weeks since Treatment Initiation
90
80
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
0
10
20
30
40
50
60
70
80
90
100

FIG. 10C



Non-small-cell lung cancer 10 mg/kg
First occurrence of new lesion
Patient off study
Change in Target Lesions from Baseline (%)
Weeks since Treatment Initiation
80
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
0
10
20
30
40
50
60
70
80

FIG. 10D




FIG. 11




FIG. 12




FIG. 13



Change in target lesions from baseline (%)
300
250
200
150
100
50
0
-20
-40
-60
-80
-100
0
10
20
30
40
50
60
70
80
90
100
110
120
Weeks since treatment initiation

FIG. 14A



250
200
150
100
50
0
-50
-100
Change in target lesions from baseline (%)
Patients

FIG. 14B




FIG. 15



Change in target lesions from baseline (%)
300
250
200
150
100
50
0
-20
-40
-60
-80
-100
0
10
20
30
40
50
60
70
80
90
100
110
120
Weeks since treatment initiation

FIG. 16A



Change in target lesions from baseline (%)
300
250
200
150
100
50
0
-20
-40
-60
-80
-100
0
10
20
30
40
50
60
70
80
90
100
110
120
Weeks since treatment initiation

FIG. 16B



Change in target lesions from baseline (%)
300
250
200
150
100
50
0
-20
-40
-60
-80
-100
0
10
20
30
40
50
60
70
80
90
100
110
120
Weeks since treatment initiation

FIG. 16C



12 weeks
3.7 gastric mass
3.2 cm peripancreatic mass
Pretreatment
10 cm gastric mass
5 cm peripancreatic mass

FIG. 17



Change in target lesions from baseline (%)
300
250
200
150
100
50
0
-20
-40
-60
-80
-100
0
10
20
30
40
50
60
70
80
90
100
110
120
Weeks since treatment initiation

FIG. 18A



Change in target lesions from baseline (%)
300
250
200
150
100
50
0
-20
-40
-60
-80
-100
0
10
20
30
40
50
60
70
80
90
100
110
120
Weeks since treatment initiation

FIG. 18B



Change in target lesions from baseline (%)
250
200
150
100
50
0
-50
-100
Patients

FIG. 18C